



SAFETY DATA SHEET

Revision date 16-Jun-2025

Version 4

Page 1 / 14

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Pamidronate Disodium Injection (Hospira, Inc.)
Product Code(s) PZ01430
Synonyms PAMISOL
Trade Name: Not applicable
Chemical Family: Bisphosphonate

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Pfizer Ireland Pharmaceuticals
OSG Building
Ringaskiddy, Co. Cork.
Ireland
+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

Reproductive toxicity Category 1B

OSHA Classification

Hazards not otherwise classified (HNOC)
Not applicable

Hazards classified under paragraph (d)(1)(ii) of 1910.1200
Not applicable

2.2. Label elements



Signal word Danger

SAFETY DATA SHEET

Product Name Pamidronate Disodium Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 2 / 14
Version 4

Hazard statements

H360FD - May damage fertility. May damage the unborn child

Precautionary Statements - EU (§28, 1272/2008)

P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical advice/attention
P405 - Store locked up
P501 - Dispose of contents/container in accordance with local, regional, national, and international regulations as applicable

2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

No information available

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Pamidronate disodium (CAS #: 57248-88-1)	0.3-0.9		260-647-1	Acute Tox. 4 (H302) Repr.1B (H360FD) Eye Irrit. 2A (H319) Skin Irrit. 2 (H315)	Not classified	No data available	No data available
Sodium hydroxide (CAS #: 1310-73-2)	**	-	215-185-5 (011-002-00-6)	Skin Corr.1A (H314)	Eye Irrit. 2 :: 0.5%<=C<2% Skin Corr. 1A :: C>=5% Skin Corr. 1B :: 2%<=C<5% Skin Irrit. 2 :: 0.5%<=C<2%	No data available	No data available

SAFETY DATA SHEET

Product Name Pamidronate Disodium Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 3 / 14
Version 4

+ Phosphoric acid (CAS #: 7664-38-2)	**		231-633-2 (015-011-00-6)	Skin Corr. 1B (H314)	Eye Irrit. 2 :: 10%≤C<25% Skin Corr. 1B :: C≥25% Skin Irrit. 2 :: 10%≤C<25%	No data available	No data available
---	----	--	-----------------------------	-------------------------	--	----------------------	----------------------

NonHazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified	Not classified	No data available	No data available
Mannitol (CAS #: 69-65-8)	*	-	200-711-8	Not classified	Not classified	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate No information available

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available
+ Phosphoric acid 7664-38-2	1530	2740	0.9615	No data available	No data available
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Mannitol 69-65-8	13500	No data available	No data available	No data available	No data available

This product does not contain candidate substances of very high concern at a concentration ≥0.1% (Regulation (EC) No. 1907/2006 (REACH), Article 59).

Additional information

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. * Proprietary
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention

SAFETY DATA SHEET

Product Name Pamidronate Disodium Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 4 / 14
Version 4

immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO₂, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical Fine particles (such as dust and mists) may fuel fires/explosions.

Hazardous combustion products Formation of toxic gases is possible during heating or fire.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

5.3. Advice for firefighters

Special protective equipment and precautions for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Contain the source of the spill or leak. Collect spilled material by a method that controls dust generation. Avoid use of a filtered vacuum to clean spills of dry solids. Clean contaminated surface thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

SAFETY DATA SHEET

Product Name Pamidronate Disodium Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 5 / 14
Version 4

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Handle in accordance with good industrial hygiene and safety practice.

General hygiene considerations

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions

Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s)

Pharmaceutical product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Sodium hydroxide

ACGIH OEL (Ceiling)	2 mg/m ³
ACGIH TLV	Ceiling: 2 mg/m ³
Austria	TWA-TMW: 2 mg/m ³ ; inhalable fraction
	STEL-KZGW: 4 mg/m ³ (8 X 5 min); inhalable fraction
Bulgaria	TWA: 2.0 mg/m ³ ; alkaline aerosols
Czech Republic	1 mg/m ³
	Ceiling: 2 mg/m ³
Denmark	Ceiling: 2 mg/m ³ ;
Estonia	TWA: 1 mg/m ³ ;
	STEL: 2 mg/m ³ ;
Finland	Ceiling: 2 mg/m ³ ;
France	2 mg/m ³
Hungary	TWA-AK: 1 mg/m ³ ;
	STEL-CK: 2 mg/m ³ ;
Ireland	STEL: 2 mg/m ³ ;
Ceiling Limit Value	2 mg/m ³
Latvia	TWA: 0.5 mg/m ³ ;
Poland	TWA-NDS: 0.5 mg/m ³ ;
	STEL-NDSch: 1 mg/m ³ ;
Romania	TWA: 1 mg/m ³ ;
	STEL: 3 mg/m ³ ;
Slovakia	TWA: 2 mg/m ³ ;
Spain	STEL (VLA-EC): 2 mg/m ³ ;
Switzerland	TWA-MAK: 2 mg/m ³ ; inhalable dust
	STEL-KZGW: 2 mg/m ³ ; inhalable dust
OSHA PEL	TWA: 2 mg/m ³
	(vacated) Ceiling: 2 mg/m ³
United Kingdom	STEL: 2 mg/m ³ ;

+ Phosphoric acid

SAFETY DATA SHEET

Product Name Pamidronate Disodium Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 6 / 14
Version 4

ACGIH TLV	TWA: 1 mg/m ³ STEL: 3 mg/m ³
Austria	TWA-TMW: 1 mg/m ³ ; STEL-KZGW: 2 mg/m ³ (4 X 15 min);
Bulgaria	TWA: 1.0 mg/m ³ ; STEL: 2.0 mg/m ³ ;
Czech Republic	1 mg/m ³ Ceiling: 2 mg/m ³
Denmark	TWA: 1 mg/m ³ ; STEL: 2 mg/m ³ ;
Estonia	TWA: 1 mg/m ³ ; vapor STEL: 2 mg/m ³ ; vapor
European Union	TWA: 1 mg/m ³ ; STEL: 2 mg/m ³ ;
Finland	TWA: 1 mg/m ³ ; STEL: 2 mg/m ³ ;
France	1 mg/m ³
Germany DFG	TWA-MAK: 2 mg/m ³ ; I(2);inhalable fraction Peak: 4 mg/m ³ ; inhalable fraction
Germany TRGS	TWA-AGW; 2 mg/m ³ (exposure factor 2); inhalable fraction
Hungary	TWA-AK: 1 mg/m ³ ; STEL-CK: 2 mg/m ³ ;
Ireland	TWA: 1 mg/m ³ ; STEL: 2 mg/m ³ ;
Italy MDLPS	TWA: 1 mg/m ³ ; STEL: 2 mg/m ³ ;
Latvia	TWA: 1 mg/m ³ ; STEL: 2 mg/m ³ ;
Netherlands	TWA: 1 mg/m ³ ; STEL: 2 mg/m ³ ;
Poland	TWA-NDS: 1 mg/m ³ ; STEL-NDSch: 2 mg/m ³ ;
Romania	TWA: 1 mg/m ³ ; STEL: 2 mg/m ³ ;
Slovakia	TWA: 1 mg/m ³ ; Ceiling: 2 mg/m ³ ;
Spain	TWA-(VLA-ED): 1 mg/m ³ ; STEL (VLA-EC): 2 mg/m ³ ;
Switzerland	TWA-MAK: 2 mg/m ³ ; inhalable dust STEL-KZGW: 4 mg/m ³ ; inhalable dust
OSHA PEL	TWA: 1 mg/m ³ (vacated) TWA: 1 mg/m ³ (vacated) STEL: 3 mg/m ³
United Kingdom	TWA: 1 mg/m ³ ; STEL: 2 mg/m ³ ;
Mannitol	
Russia	MAC: 10 mg/m ³

Pfizer Occupational Exposure Band (OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

SAFETY DATA SHEET

Product Name Pamidronate Disodium Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 7 / 14
Version 4

8.2. Exposure controls

Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).

Thermal hazards

No information available.

Environmental exposure controls

No information available.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Appearance	Solution
Physical state	Liquid
Color	Clear, colorless
Odor	No information available.
Odor threshold	No information available

Property

Melting point / freezing point
Boiling point or initial boiling point and boiling range
Flammability (solid, gas)
Lower and upper explosion limit/flammability limit
 Lower explosion limit
 Upper explosion limit
Flash point
Autoignition temperature
Decomposition temperature
 SADT (°C)

Values

No data available
No data available
No data available
No data available
No data available
No data available
No data available
No data available
No data available

SAFETY DATA SHEET

Product Name Pamidronate Disodium Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 8 / 14
Version 4

pH	6.0-7.4
pH (as aqueous solution)	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Solubility	No data available
Vapor pressure	No data available
Density and/or relative density	No data available
Bulk density	No data available
Liquid Density	No data available
Vapor density	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available

9.2. Other information

Molecular formula	Mixture
Molecular weight	Mixture

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No information available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information: The information included in this section describes the potential hazards of the individual ingredients

Short term May cause eye and skin irritation (based on components)

Known Clinical Effects: Common adverse effects include fever, bone pain, back pain, vomiting, decreased red blood cell count (anemia), electrolyte imbalance, and kidney effects.

SAFETY DATA SHEET

Product Name Pamidronate Disodium Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 9 / 14
Version 4

Acute toxicity	Based on available data, the classification criteria are not met.
Serious eye damage/eye irritation	Based on available data, the classification criteria are not met.
Skin corrosion/irritation	Based on available data, the classification criteria are not met.
Respiratory or skin sensitization	Based on available data, the classification criteria are not met.
STOT - single exposure	Based on available data, the classification criteria are not met.
STOT - repeated exposure	Based on available data, the classification criteria are not met.
Reproductive toxicity	Based on available data, the classification criteria are not met.
Germ cell mutagenicity	Based on available data, the classification criteria are not met.
Carcinogenicity	Based on available data, the classification criteria are not met.
Aspiration hazard	Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Pamidronate disodium

Rat Oral LD50 1560 mg/kg
Mouse Oral LD50 625 mg/kg
Rat IV LD50 50 mg/kg

+ Phosphoric acid

Rat Oral LD50 1530 mg/kg
Rabbit Dermal LD 50 2730 mg/kg

Sodium hydroxide

Mouse IP LD50 40 mg/kg

Mannitol

Rat Oral LD 50 13500 mg/kg
Mouse Oral LD 50 22 g/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Sodium hydroxide	= 325 mg/kg (Rat)	= 1350 mg/kg (Rabbit)	-
+ Phosphoric acid	= 1530 mg/kg (Rat)	= 2740 mg/kg (Rabbit)	= 3846 mg/m ³ (Rat) 1 h
Water	> 90 mL/kg (Rat)	-	-
Mannitol	= 13500 mg/kg (Rat)	-	-

Irritation / Sensitization: (Study Type, Species, Severity)

Pamidronate disodium

Eye Irritation Rabbit Severe
Skin Irritation Rabbit Moderate

+ Phosphoric acid

Eye Irritation Rabbit Severe
Skin Irritation Rabbit Severe

Sodium hydroxide

Eye Irritation Rabbit Severe
Skin Irritation Rabbit Severe

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Pamidronate disodium

3 Month(s) Dog IV infusion 2 mg/kg/week NOAEL Kidney
3 Month(s) Rat IV infusion 2 mg/kg/week NOAEL Kidney

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Pamidronate disodium

Embryo / Fetal Development Rat Oral 150 mg/kg/day LOAEL Developmental toxicity
Embryo / Fetal Development Rabbit Oral 150 mg/kg/day LOAEL Developmental toxicity, Maternal Toxicity

SAFETY DATA SHEET

Product Name Pamidronate Disodium Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 10 / 14
Version 4

Embryo / Fetal Development Rat Intravenous 6 mg/kg/day LOAEL Developmental toxicity, Maternal Toxicity
2 Generation Reproductive Toxicity Rat Oral 150 mg/kg/day LOAEL Fertility

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Pamidronate disodium

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative
Sister Chromatid Exchange Not specified Negative
Micronucleus Rat Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Pamidronate disodium

80 Week(s) Mouse Oral Not specified NOAEL Not carcinogenic

104 Week(s) Rat Oral Not specified Benign tumors

Carcinogenicity Not listed as a carcinogen by IARC, NTP or US OSHA.

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Pamidronate disodium

Daphnia magna (Water Flea) NOEC 48 hours 15 mg/L

+ Phosphoric acid

Gambusia affinis (Mosquitofish) LC50 96 hours 3-3.5 mg/L

Daphnia magna (Water Flea) EC-50 12 4.6 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Pamidronate disodium

Aspergillus niger (Fungus) > 1000 mg/L

Bacillus subtilis (Bacterium) MIC 200 mg/L

Clostridium perfringens (Bacterium) MIC 200 mg/L

Nostoc sp. (Freshwater Cyanobacteria) MIC > 1000 mg/L

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

SAFETY DATA SHEET

Product Name Pamidronate Disodium Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 11 / 14
Version 4

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment Based on available data, the classification criteria are not met.

Chemical name	PBT and vPvB assessment
+ Phosphoric acid	Not PBT/vPvB PBT assessment does not apply
Sodium hydroxide	Not PBT/vPvB PBT assessment does not apply

12.6. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

12.7. Other adverse effects

Other adverse effects No information available.

PMT or vPvM properties Based on available data, the classification criteria are not met.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number: Not applicable
UN proper shipping name: Not applicable
Transport hazard class(es): Not applicable
Packing group: Not applicable
Environmental Hazard(s): Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Pamidronate disodium

SAFETY DATA SHEET

Product Name Pamidronate Disodium Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 12 / 14
Version 4

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	260-647-1
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 4
Sodium hydroxide	
CERCLA/SARA Section 313 de minimus %	Not Listed
Hazardous Substances RQs	1000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	215-185-5
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6
+ Phosphoric acid	
CERCLA/SARA Section 313 de minimus %	Not Listed
Hazardous Substances RQs	5000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-633-2
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6
Water	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-791-2
AICS	Present
Mannitol	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	200-711-8
AICS	Present

National regulations

Germany

Chemical Prohibition Ordinance (ChemVerbotsV)

Not applicable

TRGS 905

Not applicable

Switzerland

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018 Not applicable

Storage of Hazardous Material Not applicable

WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20 Not applicable

Major Accidents Ordinance SR 814.012 Not applicable

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This

SAFETY DATA SHEET

Product Name Pamidronate Disodium Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 13 / 14
Version 4

product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Sodium hydroxide 1310-73-2	75	-
+ Phosphoric acid 7664-38-2	75	-

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

Explosives Precursors Marketing and Use (2019/1148)

Not applicable

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDL - Canadian Domestic Substances List/Non-Domestic Substances List

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

KECL - Korean Existing Chemicals Inventory

PICCS - Philippines Inventory of Chemicals and Chemical Substances

AICS - Australian Inventory of Chemical Substances

NZIoC - New Zealand Inventory of Chemicals

TCSI - Taiwan Chemical Substance Inventory

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H302 - Harmful if swallowed H360FD - May damage fertility. May damage the unborn child H319 - Causes serious eye irritation

H315 - Causes skin irritation H314 - Causes severe skin burns and eye damage

Data Sources: Publicly available toxicity information. Safety data sheets for individual ingredients.

Reason for revision Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Revision date 16-Jun-2025

SAFETY DATA SHEET

Product Name Pamidronate Disodium Injection (Hospira, Inc.)
Revision date 16-Jun-2025

Page 14 / 14
Version 4

Prepared By

Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.